Pynegabine
| Clinical data | |
|---|---|
| Other names | HN-37 |
| Routes of administration | Oral[1][2] |
| Drug class | Kv7.2 and Kv7.3 potassium channel opener |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C20H21FN2O2 |
| Molar mass | 340.398 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pynegabine (developmental code name HN37) is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of epilepsy in China.[3][1][2] The drug is an analogue of flupirtine and retigabine (ezogabine).[1][2][4] However, it shows 55-fold greater potency in activating Kv7.2 channels and 127-fold greater potency in activating Kv7.3 channels compared to retigabine in vitro.[1] In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison.[1][2] The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao.[3][1][2] As of 2026, it is in phase 2 clinical trials for epilepsy.[3][1][2]
See also
References
- ^ a b c d e f g Perucca E, Taglialatela M (March 2025). "Targeting Kv7 Potassium Channels for Epilepsy". CNS Drugs. 39 (3): 263–288. doi:10.1007/s40263-024-01155-3. PMC 11850491. PMID 39853501.
- ^ a b c d e f Pelorosso C, Balestrini S, Guerrini R (May 2026). "Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?". Expert Opinion on Emerging Drugs: 1–8. doi:10.1080/14728214.2026.2675274. hdl:2158/1473832. PMID 42153277.
- ^ a b c "Delving into the Latest Updates on Pynegabine with Synapse". Synapse. 7 March 2026. Retrieved 31 May 2026.
- ^ Zhang YM, Xu HY, Hu HN, Tian FY, Chen F, Liu HN, et al. (May 2021). "Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate". Journal of Medicinal Chemistry. 64 (9): 5816–5837. doi:10.1021/acs.jmedchem.0c02252. PMID 33929863.